Researchers analyzed data from a 28-day clinical study of 146 patients, half of which took inhaled budesonide — sold as AstraZeneca’s Pulmicort — twice a day.
The drug cut the risk of urgent care or hospitalization by 90 percent within the study period and was also tied to a “quicker resolution of fever, symptoms, and fewer persistent symptoms.”
The study findings were published Feb. 4 on the medRxiv preprint server. The study has yet to be peer reviewed.
More articles on patient safety and outcomes:
Roche arthritis drug reduces COVID-19 death risk, Oxford research suggests
FDA updates guidance on ventilator splitting
Joint Commission issues alert on providing equitable care during pandemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
